Arthur E. Frankel

Affiliations: 
Wake Forest University, Winston-Salem, NC, United States 
 2013- University of Texas Southwestern Medical Center, Dallas, TX, United States 
Area:
Oncology, Biochemistry, Molecular Biology
Website:
http://profiles.utsouthwestern.edu/profile/138072/arthur-frankel-biography.html
Google:
"Arthur Frankel"
Bio:

http://www.pnas.org/content/73/10/3705.short
http://jvi.asm.org/content/21/1/153.short

Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Bekdash A, Darwish M, Timsah Z, et al. (2015) Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF). Translational Oncology. 8: 347-57
Burrage LC, Sun Q, Elsea SH, et al. (2015) Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. Human Molecular Genetics
Frankel AE, Woo JH, Ahn C, et al. (2015) Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 100: 794-800
Bachanova V, Frankel AE, Cao Q, et al. (2015) Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1267-72
Khoury O, Ghazale N, Stone E, et al. (2015) Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. Journal of Neuro-Oncology. 122: 75-85
Rakheja D, Fuda F, Vandergriff T, et al. (2015) Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. Human Pathology. 46: 322-6
Agrawal V, Woo JH, Mauldin JP, et al. (2014) In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts. Melanoma Research. 24: 556-67
Frolova O, Benito J, Brooks C, et al. (2014) SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. British Journal of Haematology. 166: 862-74
Frankel AE, Woo JH, Ahn C, et al. (2014) Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 124: 385-92
Frankel AE. (2013) Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity. Clinical Pharmacology : Advances and Applications. 5: 1-3
See more...